Rising like the phoenix?

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 34, Issue 10, 2014, Pages 2182-2183

  Plow, Edward F ^a   Das, Mitali ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Platelet; Platelet aggregation; Thrombosis; IIb 3; IIb 3 antagonist

Indexed keywords

ABCIXIMAB; ALPHAIIBBETA3 ANTAGONIST; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; RUC 4; TIROFIBAN; UNCLASSIFIED DRUG; ANTITHROMBOCYTIC AGENT; FIBRINOGEN RECEPTOR; FIBRINOLYTIC AGENT; PYRIMIDINONE DERIVATIVE; RUC-4 COMPOUND; THIADIAZOLE DERIVATIVE;

ACUTE CORONARY SYNDROME; ADVERSE DRUG REACTION; BLEEDING; CARDIAC PATIENT; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; CONFORMATIONAL TRANSITION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SOLUBILITY; EDITORIAL; HEART INFARCTION; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; LIGAND BINDING; MACACA FASCICULARIS; MORTALITY; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTOPENIA; ANIMAL; ANTAGONISTS AND INHIBITORS; CAROTID STENOSIS; DRUG EFFECTS; EMERGENCY HEALTH SERVICE; MALE; MYOCARDIAL INFARCTION; THROMBOCYTE; THROMBOSIS;

ANIMALS; BLOOD PLATELETS; CAROTID STENOSIS; EMERGENCY MEDICAL SERVICES; FIBRINOLYTIC AGENTS; HUMANS; MALE; MYOCARDIAL INFARCTION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PYRIMIDINONES; THIADIAZOLES; THROMBOSIS;

EID: 84913554266     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.114.304486     Document Type: Editorial

References (18)

1. Bledzka K, Smyth SS, Plow EF. Integrin αIIbβ3: from discovery to efficacious therapeutic target. Circ Res. 2013;112:1189-1200.
2. Coller BS. Translating from the rivers of Babylon to the coronary bloodstream. J Clin Invest. 2012;122:4293-4299.
3. Bosch X, Marrugat J, Sanchis J. Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes. Cochrane Database Syst Rev. 2013;11:CD002130.
4. Cox D. Oral GPIIb/IIIa antagonists: what went wrong? Curr Pharm Des. 2004;10:1587-1596.
5. Chew DP, Bhatt DL, Sapp S, Topol EJ. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials. Circulation. 2001;103:201-206.
6. Ndrepepa G, Guerra E, Schulz S, et al. Weight of the bleeding impact on early and late mortality after percutaneous coronary intervention [published online ahead of print May 16, 2014]. J Thromb Thrombolysis. doi: 10.1007/s11239-014-1084-3. http://link.springer.com/article/10.1007% 2Fs11239-014-1084-3.
7. Ndrepepa G, Kastrati A, Neumann FJ, et al. Five-year outcome of patients with acute myocardial infarction enrolled in a randomised trial assessing the value of abciximab during coronary artery stenting. Eur Heart J. 2004;25:1635-1640.
8. Tcheng JE. Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: bleeding, reversal, thrombocytopenia, and retreatment. Am Heart J. 2000;139(2 Pt 2):S38-S45.
9. Tcheng JE, Kereiakes DJ, Lincoff AM, et al. Abciximab readministration: results of the ReoPro Readministration Registry. Circulation 2001;104:870-875.
10. Zhu J, Zhu J, Negri A, et al. Closed headpiece of integrin alphaIIbbeta3 and its complex with an alphaIIbbeta3-specific antagonist that does not induce opening. Blood 2010;116:5050-5059.
11. Li J, Vootukuri S, Shang Y, Negri A, Jiang JK, Nedelman M, Diacovo TG, Filizola M, Thomas CJ, Coller BS. RUC-4: a novel αIIbβ3 antagonist for prehospital therapy of myocardial infarction. Arterioscler Thromb Vasc Biol. 2014;34:2321-2329.
12. Blue R, Kowalska MA, Hirsch J, et al. Structural and therapeutic insights from the species specificity and in vivo antithrombotic activity of a novel alphaIIb-specific alphaIIbbeta3 antagonist. Blood 2009;114:195-201.
13. Frelinger AL III, Du X, Plow EF, Ginsberg MH. Monoclonal antibodies to ligand-occupied conformers of integrin αIIbβ3 (glycoprotein IIb-IIIa) alter receptor affinity, specificity and function. J Biol Chem. 1991;266:17106-17111.
14. Bougie DW, Wilker PR, Wuitschick ED, et al. Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa. Blood 2002;100:2071-2076.
15. Weitz JI, Bates SM. Beyond heparin and aspirin: new treatments for unstable angina and non-Q-wave myocardial infarction. Arch Intern Med. 2000;160:749-758.
16. Madan M, Berkowitz SD. Understanding thrombocytopenia and antigenicity with glycoprotein IIb-IIIa inhibitors. Am Heart J. 1999;138(4 Pt 2):317-326.
17. Bednar B, Cook JJ, Holahan MA, et al. Fibrinogen receptor antagonistinduced thrombocytopenia in chimpanzee and rhesus monkey associated with preexisting drug-dependent antibodies to platelet glycoprotein IIb/ IIIa. Blood 1999;94:587-599.
18. Goel K, Pinto DS, Gibson CM. Association of time to reperfusion with left ventricular function and heart failure in patients with acute myocardial infarction treated with primary percutaneous coronary intervention: a systematic review. Am Heart J. 2013;165:451-467.